JP2020507561A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507561A5 JP2020507561A5 JP2019538396A JP2019538396A JP2020507561A5 JP 2020507561 A5 JP2020507561 A5 JP 2020507561A5 JP 2019538396 A JP2019538396 A JP 2019538396A JP 2019538396 A JP2019538396 A JP 2019538396A JP 2020507561 A5 JP2020507561 A5 JP 2020507561A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 39
- 102000036639 antigens Human genes 0.000 claims 39
- 108091007433 antigens Proteins 0.000 claims 39
- 239000012634 fragment Substances 0.000 claims 39
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 101000741544 Homo sapiens Properdin Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 3
- 108010094020 polyglycine Proteins 0.000 claims 3
- 229920000232 polyglycine polymer Polymers 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000035888 Immune-mediated thrombotic thrombocytopenic purpura Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 208000004886 acquired thrombotic thrombocytopenic purpura Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022107980A JP2022153405A (ja) | 2017-01-30 | 2022-07-04 | 一価の抗プロペルジン抗体および抗体断片 |
| JP2024095141A JP2024116321A (ja) | 2017-01-30 | 2024-06-12 | 一価の抗プロペルジン抗体および抗体断片 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452187P | 2017-01-30 | 2017-01-30 | |
| US62/452,187 | 2017-01-30 | ||
| PCT/US2018/015985 WO2018140956A1 (en) | 2017-01-30 | 2018-01-30 | Monovalent anti-properdin antibodies and antibody fragments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022107980A Division JP2022153405A (ja) | 2017-01-30 | 2022-07-04 | 一価の抗プロペルジン抗体および抗体断片 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507561A JP2020507561A (ja) | 2020-03-12 |
| JP2020507561A5 true JP2020507561A5 (OSRAM) | 2021-03-04 |
| JP7101684B2 JP7101684B2 (ja) | 2022-07-15 |
Family
ID=62978808
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538396A Active JP7101684B2 (ja) | 2017-01-30 | 2018-01-30 | 一価の抗プロペルジン抗体および抗体断片 |
| JP2022107980A Pending JP2022153405A (ja) | 2017-01-30 | 2022-07-04 | 一価の抗プロペルジン抗体および抗体断片 |
| JP2024095141A Pending JP2024116321A (ja) | 2017-01-30 | 2024-06-12 | 一価の抗プロペルジン抗体および抗体断片 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022107980A Pending JP2022153405A (ja) | 2017-01-30 | 2022-07-04 | 一価の抗プロペルジン抗体および抗体断片 |
| JP2024095141A Pending JP2024116321A (ja) | 2017-01-30 | 2024-06-12 | 一価の抗プロペルジン抗体および抗体断片 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11198725B2 (OSRAM) |
| EP (1) | EP3573661A4 (OSRAM) |
| JP (3) | JP7101684B2 (OSRAM) |
| KR (2) | KR102613874B1 (OSRAM) |
| CN (2) | CN118184777A (OSRAM) |
| AU (2) | AU2018212012B2 (OSRAM) |
| BR (1) | BR112019014652A2 (OSRAM) |
| CA (1) | CA3049806A1 (OSRAM) |
| CO (1) | CO2019007686A2 (OSRAM) |
| IL (2) | IL309890A (OSRAM) |
| MX (3) | MX2019008827A (OSRAM) |
| WO (1) | WO2018140956A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201246B (zh) * | 2017-07-11 | 2023-10-27 | 亚力兄制药公司 | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 |
| EP3849304B1 (en) * | 2018-09-13 | 2024-01-10 | Regeneron Pharmaceuticals, Inc. | Complement factor h gene knockout rat as a model of c3 glomerulopathy |
| BR112022012198A2 (pt) * | 2020-01-08 | 2022-09-06 | Zydus Lifesciences Ltd | Anticorpo antiproperdina, composição, imunoconjugado, molécula biespecífica, sequência de ácido nucleico, vetor de expressão, célula hospedeira e combinação |
| US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| CN118436786A (zh) * | 2020-10-30 | 2024-08-06 | 广州市妇女儿童医疗中心 | 诊治胆道闭锁的方法 |
| WO2023023227A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors |
| US11981727B2 (en) | 2021-08-31 | 2024-05-14 | Novelmed Therapeutics, Inc | Monospecific and bispecific antibodies and antigen binding fragments thereof |
| WO2024108529A1 (en) * | 2022-11-25 | 2024-05-30 | Linno Pharmaceuticals Inc. | Properdin binding protein and use thereof |
| WO2024031049A2 (en) * | 2022-08-05 | 2024-02-08 | Alexion Pharmaceuticals, Inc. | Pharmaceutical compositions of fusion proteins and methods of use thereof |
| JP2025531719A (ja) * | 2022-08-31 | 2025-09-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 鎌状赤血球症の治療のための融合ポリペプチドの投薬及び投与 |
| EP4395825A4 (en) * | 2022-11-25 | 2025-08-20 | Linno Pharmaceuticals Inc | PROPERDIN-BINDING PROTEIN AND ITS USE |
| CN120399074A (zh) * | 2023-06-02 | 2025-08-01 | 安徽金百奥生物科技有限公司 | 一种与人dr3胞外域高亲和力的纳米抗体 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US7423128B2 (en) * | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| MX2007008982A (es) | 2005-01-25 | 2007-12-06 | Cell Therapeutics Inc | Conjugados de proteinas biologicamente activas que tienen una vida media modificada in vivo. |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR20180002911A (ko) * | 2005-11-04 | 2018-01-08 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| WO2011112850A2 (en) * | 2010-03-10 | 2011-09-15 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-properdin antibodies |
| DK2262831T3 (en) * | 2008-03-03 | 2015-04-27 | Novelmed Therapeutics Inc | ANTI-Properdin ANTIBODIES |
| KR20120105405A (ko) | 2009-06-23 | 2012-09-25 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체 단백질에 결합하는 이중특이적 항체 |
| UY32920A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Moleculas de unión biespecíficas para la terapia anti-angiogénesis |
| CA2813087C (en) | 2010-09-28 | 2020-07-21 | Amylin Pharmaceuticals, Llc | Engineered polypeptides having enhanced duration of action |
| ES2723775T3 (es) | 2010-11-08 | 2019-09-02 | Ablynx Nv | Polipéptidos que se unen a CXCR2 |
| EP2726103B1 (en) * | 2011-07-01 | 2018-09-05 | The Trustees Of The University Of Pennsylvania | Anti-properdin antibodies and uses thereof |
| WO2013009545A1 (en) * | 2011-07-08 | 2013-01-17 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action with reduced immunogenicity |
| AP2014007761A0 (en) * | 2011-12-21 | 2014-07-31 | Novartis Ag | Compositions and methods for antibodies targeting factor P |
| CN104114187A (zh) * | 2011-12-28 | 2014-10-22 | 诺沃姆德治疗公司 | 去糖基化的人类抗体、其融合蛋白质及用途 |
| EP2904014A4 (en) | 2012-10-04 | 2016-09-28 | Novelmed Therapeutics Inc | FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN110003335B (zh) * | 2019-04-12 | 2023-07-04 | 深圳普瑞金生物药业股份有限公司 | Cd47单域抗体、核酸及试剂盒 |
-
2018
- 2018-01-30 CN CN202410325026.7A patent/CN118184777A/zh active Pending
- 2018-01-30 CN CN201880008892.6A patent/CN110831626B/zh active Active
- 2018-01-30 BR BR112019014652-0A patent/BR112019014652A2/pt unknown
- 2018-01-30 KR KR1020197021910A patent/KR102613874B1/ko active Active
- 2018-01-30 WO PCT/US2018/015985 patent/WO2018140956A1/en not_active Ceased
- 2018-01-30 IL IL309890A patent/IL309890A/en unknown
- 2018-01-30 EP EP18744926.9A patent/EP3573661A4/en active Pending
- 2018-01-30 MX MX2019008827A patent/MX2019008827A/es unknown
- 2018-01-30 KR KR1020237042534A patent/KR20230173731A/ko not_active Ceased
- 2018-01-30 US US16/479,335 patent/US11198725B2/en active Active
- 2018-01-30 AU AU2018212012A patent/AU2018212012B2/en active Active
- 2018-01-30 IL IL267898A patent/IL267898B2/en unknown
- 2018-01-30 CA CA3049806A patent/CA3049806A1/en active Pending
- 2018-01-30 JP JP2019538396A patent/JP7101684B2/ja active Active
-
2019
- 2019-07-17 CO CONC2019/0007686A patent/CO2019007686A2/es unknown
- 2019-07-25 MX MX2023007840A patent/MX2023007840A/es unknown
- 2019-07-25 MX MX2023004333A patent/MX2023004333A/es unknown
-
2021
- 2021-11-09 US US17/522,028 patent/US12497445B2/en active Active
-
2022
- 2022-07-04 JP JP2022107980A patent/JP2022153405A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095141A patent/JP2024116321A/ja active Pending
-
2025
- 2025-02-03 AU AU2025200709A patent/AU2025200709A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507561A5 (OSRAM) | ||
| JP2022153405A5 (OSRAM) | ||
| JP2024116321A5 (OSRAM) | ||
| JP2024063213A (ja) | 改良された血清アルブミン結合剤 | |
| AU2016351710B2 (en) | Improved serum albumin-binding immunoglobulin variable domains | |
| JP6529498B2 (ja) | ＥＧＦＲｖＩＩＩに対して特異的な抗体結合部位 | |
| RU2687588C2 (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| JP2020062036A5 (OSRAM) | ||
| JP2014508748A5 (OSRAM) | ||
| JP2019535763A5 (OSRAM) | ||
| JP2015522252A5 (OSRAM) | ||
| JP2019505527A5 (OSRAM) | ||
| JP2017522903A5 (OSRAM) | ||
| JP2016529229A5 (OSRAM) | ||
| JP2019503990A5 (OSRAM) | ||
| JP2016512551A5 (OSRAM) | ||
| JP2014533239A5 (OSRAM) | ||
| RU2018112861A (ru) | Стабильные антитела, связывающиеся с несколькими антигенами | |
| JP2018505674A5 (OSRAM) | ||
| JP2016527314A5 (OSRAM) | ||
| JP2016511277A5 (OSRAM) | ||
| JP2014509861A (ja) | Ｃｄ７０に対する抗体 | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2020524661A5 (OSRAM) | ||
| AU2013341349A1 (en) | Combination therapies using anti-Pseudomonas Psl and PcrV binding molecules |